White Paper

Considerations For The Clinical Development of Cell & Gene Therapies (Part 2: Gene Therapies)

Lab cell and gene pipette GettyImages-162264253

Advances in stem cell technology, combined with the increasing prevalence of chronic diseases, are driving rapid growth in the regenerative medicine category, which is predicted to generate $39.33 billion in revenue by 2023.

The Alliance for Regenerative Medicine, in its latest progress report, noted that in addition to the 1320 ongoing industry-sponsored trials worldwide, as well as a similar number (1328) of ongoing trials sponsored by non-industry groups, financing for regenerative medicine and advanced therapies has reached new heights, with $14.1 billion raised in the first half of 2021—71% of what was raised in full-year 2020. That surge in investment has made the first half of 2021 the strongest half-year on record, and puts the sector on pace to outperform 2020, during which nearly $20 billion was raised despite the COVID-19 pandemic.

These trends provided the impetus for Considerations for the Clinical Development of Cell & Gene Therapies, a two-part panel discussion featuring C-suite leaders from advanced therapy companies at the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.

In this white paper, we share the exclusive insights from Part 2 of this insightful discussion moderated by Precision’s David Parker.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene